I was looking through the briefing docs for the July 23-24 PCAC meeting and something kept jumping out at me. It's not just that FDA is leaning toward keeping all seven off the 503A list, it's that the use case they're actually reviewing is often totally disconnected from why any of us are running these things.

Epitalon is the one that got me. FDA reviewed it for insomnia. That's it. Not telomeres, not longevity, not any of the anti-aging stuff that's basically the entire reason people know this peptide exists.

Same deal with BPC-157. The reviewed indication is ulcerative colitis specifically. Meanwhile pretty much nobody in this sub is running BPC for UC, it's tendons, joints, general gut and recovery stuff.

Semax was reviewed for cerebral ischemia, which is a stroke related use. Not exactly the same as running it for focus.

TB-500, KPV, MOTS-c, and DSIP line up a lot closer to their actual community use honestly, wound healing, inflammation, metabolic stuff, sleep.

I get why this happens, someone nominates a peptide for a specific indication and that's what gets evaluated, it's not really FDA's job to review "what biohackers are actually doing with it." But it does mean the review process and the actual demand driving this whole market are kind of talking past each other.

I wonder what you guys think. For whatever you're personally taking, does FDA's reviewed use match your actual reason at all, or is it not even close?

Meeting page: https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026

More stories at r/PeptideTides

Worth flagging for anyone tracking the July PCAC meeting. FDA career scientists posted a recommendation Monday saying there isn't enough evidence to allow certain peptides to be produced by compounding pharmacies, which contradicts Health Secretary RFK Jr's push to expand access to these products.

The recommendation went up quietly, around the same time HHS added several new members to the panel that will review some of these peptides next month.

The panel composition is the part I'd pay closest attention to. Earlier versions of the FDA's compounding panel were mostly academics from places like Duke, Harvard, and Johns Hopkins, and they voted against a string of peptide ingredients as too risky.

The new group instead includes more than half a dozen panelists who run clinics, online businesses, or pharmacies that specialize in peptides.

AP's reporting names specific examples, including a Florida clinic operator who sells peptide, vitamin, testosterone, and weight loss injections, and a panelist who charges for "peptide and hormone" consultations while promoting BPC-157 and GHK-Cu to a large social following.

So you've got career staff saying the science doesn't support reclassification, while the review panel itself is being staffed with people who have financial ties to the industry being reviewed. That tension is the story here, not just the staff recommendation on its own.

For context on the broader timeline: FDA is set to hold a two-day advisory committee meeting in late July to discuss seven peptides including BPC-157, with a second panel taking up five more peptides by February 2027.

Sources:

https://www.washingtonpost.com/health/2026/06/30/fda-staff-recommendation-undercuts-rfk-jrs-push-expand-peptides/

https://www.washingtontimes.com/news/2026/jun/29/fda-panel-peptides-include-experts-who-promote-unproven-chemicals/

https://www.biopharmadive.com/news/fda-peptides-rfk-advisory-committee-restrictions/817685/

More stories at r/PeptideTides

​

This broke into mainstream news this week and it's worth a proper writeup for this community, because it touches on something a lot of us have been watching closely: who actually gets access to retatrutide, and how.

On June 23, STAT News reported that Eli Lilly and the FDA quietly granted a single unnamed individual access to retatrutide through the FDA's expanded access pathway, what most people know as "compassionate use." The drug has been generating enormous interest, with trial data showing bariatric-surgery-level weight loss, and plenty of people in spaces like this one have already been sourcing it through gray-market channels rather than wait on an approval timeline that has no firm end date.

So who got it through the front door?

Dr. Ranganath Muniyappa, a senior clinician at the NIH, filed the expanded access request on behalf of a 79-year-old male patient diagnosed with refractory obesity, obstructive sleep apnea, and pulmonary hypertension. Muniyappa reportedly advised against bariatric surgery given the patient's age and comorbidities, and Eli Lilly agreed to provide the drug. The FDA authorized the request. Three sources familiar with the situation spoke to STAT anonymously, citing fear of reprisals.

The 79-year-old detail is what set everything off. Trump turned 80 on June 14. He also used this exact same compassionate use pathway in 2020 to access Regeneron's monoclonal antibody cocktail during COVID.

The White House denied it. Spokesman Kush Desai posted on X that the application "was not for the President" and went after the STAT reporter, Lizzy Lawrence, calling her "an unserious gossip columnist." Lawrence noted publicly that she had asked Desai, the FDA, and HHS directly, multiple times, whether the patient was Trump before publishing. Nobody answered her.

The denial itself raised more questions than it resolved. When STAT asked whether Trump had obstructive sleep apnea or pulmonary hypertension, Desai pointed to Trump's most recent medical evaluation as covering those questions. It doesn't.

Neither condition appears anywhere in that document.

Outside clinicians also questioned whether the listed diagnoses would normally clear the bar for compassionate use. Jamy Ard, chief science officer at Advocate Health, told STAT that compassionate use is typically reserved for terminal illness or conditions with a very long or marginal path to approval. Refractory obesity with sleep apnea and pulmonary hypertension is serious, but experts weren't convinced it fits the standard profile.

The ClinicalTrials.gov listing for the request is also oddly sparse, with no condition listed, no eligibility criteria, and no location.

On the political side, Senator Maggie Hassan sent a letter to RFK Jr. asking whether the administration used the compassionate use pathway to give a "highly anticipated medication" to a single well-connected individual for free, while millions of Americans remain locked out of access entirely.

For this community specifically, that last part is the real issue regardless of who the patient is.

Retatrutide hits GLP-1, GIP, and glucagon receptors simultaneously, and trial data has shown 24 to 28% body weight reduction over roughly 72 to 80 weeks.

Clinical trial enrollment is essentially the only legitimate access path right now, and most people can't get in. That gap is driving everything happening in the gray market.

Whether the patient is Trump or someone else entirely, a single unnamed 79-year-old got access to the most sought-after metabolic drug in development while everyone else waits or sources it outside sanctioned channels. That's the part worth sitting with.

Sources

STAT News original report:

https://www.statnews.com/2026/06/23/eli-lilly-unusual-weight-loss-drug-trial-compassionate-use-retatrutide-trump/

STAT News follow-up (Hassan/RFK Jr. letter):

https://www.statnews.com/2026/06/25/senate-hassan-questions-rfk-jr-eli-lilly-retatrutide-trial-trump/

White House denial coverage (MS NOW):

https://www.ms.now/news/white-house-trump-weight-loss-drug

Hassan letter coverage (MS NOW): https://www.ms.now/news/maggie-hassan-retatrutide-patient-white-house

ClinicalTrials.gov listing:

https://clinicaltrials.gov/study/NCT07629401

More stories at r/PeptideTides

The picture is 2 days worth of hair from the shower. Doesn’t include literally all day of loss. I cannot run my hands through my hair (very lightly) without at least 5-10 stands every single time.

Started tirz aug ‘25. Have lost 80 pounds so far. Currently on 10mg, split dose Sunday and Wednesday evening.
Hair loss was happening around February. Started researching. Landed on GHKCU, of course. Turned 40 in March and ordered GHKCU. Began 2mg daily May 11. Coming up on 7 weeks of use, daily. I don’t plan to cycle as research has led me to believe it’s not needed.

I see zero difference and the hair loss is WORSE. Way worse than beginning of the year.
I research and I’ve decided to start 3mg daily come Sunday June 28. Then came across AHKCU. And supposedly AH is infinitely better than GH.

I guess I’m asking, has this happened to you but the GH has helped after a couple months with hair loss??
Or did you switch to AH because of hair loss and you’re having success?

Let me know because even tho I’ve lost a significant amount of weight, my confidence is deteriorating due to being practically bald. 😔

I've seen them on finnrick and I would like to know if any of you had any experience with it. They some stuff like ace 031 that are rare to find... anyone have tested it?